Academic Journal
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
| Τίτλος: | Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study |
|---|---|
| Συγγραφείς: | Shrestha, S, Gurung, M, Amatya, P, Bijukchhe, S, Bose, AS, Carter, MJ, Gautam, MC, Gurung, S, Hinds, J, Kandasamy, R, Kelly, S, Khadka, B, Maskey, P, Mujadidi, YF, O’Reilly, PJ, Pokhrel, B, Pradhan, R, Shah, GP, Wahl, B, O’Brien, KL, Knoll, MD, Murdoch, DR, Kelly, DF, Thorson, S, Voysey, M, Pollard, AJ |
| Συνεισφορές: | group, PneumoNepal study |
| Στοιχεία εκδότη: | //www.thelancet.com/journals/langlo/home |
| Έτος έκδοσης: | 2022 |
| Συλλογή: | Oxford University Research Archive (ORA) |
| Περιγραφή: | Background In Nepal, Streptococcus pneumoniae (pneumococcus) is a common cause of bacterial pneumonia in children, and is a major health concern. There are few data on the effect of vaccination on the disease or colonisation with pneumococci in the nasopharynx of children in this setting. The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the routine infant immunisation schedule in Nepal in 2015. We aimed to investigate the effect of the introduction of PCV10 on pneumococcal carriage and disease in children in Nepal. Methods We did an observational cohort study in children in Nepal. The hospital surveillance study took place in Patan Hospital, Kathmandu, and community studies in healthy children took place in Kathmandu and Okhaldhunga district. For the surveillance study, all children admitted to Patan Hospital between March 20, 2014, and Dec 31, 2019, aged between 2 months and 14 years with clinician-suspected pneumonia, were eligible for enrolment. For the community study, healthy children aged 0–8 weeks, 6–23 months, and 24–59 months were recruited from Kathmandu, and healthy children aged 6–23 months were recruited from Okhaldhunga. We assessed the programmatic effect of PCV10 introduction using surveillance for nasopharyngeal colonisation, pneumonia, and invasive bacterial disease from 1·5 years before vaccine introduction and 4·5 years after vaccine introduction. For the surveillance study, nasopharyngeal swabs, blood cultures, and chest radiographs were obtained from children admitted to Patan Hospital with suspected pneumonia or invasive bacterial disease. For the community study, nasopharyngeal swabs were obtained from healthy children in the urban and rural settings. Pneumonia outcomes were analysed using log-binomial models and adjusted prevalence ratios (aPR) comparing each calendar year after the introduction of the vaccine into the national programme with the pre-vaccine period (2014–15), adjusted for calendar month, age, and sex. Findings Between March 20, 2014, and Dec 31, ... |
| Τύπος εγγράφου: | article in journal/newspaper |
| Γλώσσα: | English |
| DOI: | 10.1016/s2214-109x(22)00281-9 |
| Διαθεσιμότητα: | https://doi.org/10.1016/s2214-109x(22)00281-9 https://ora.ox.ac.uk/objects/uuid:ebf0eb3b-d27e-4cd7-b10a-c28a98a94219 |
| Rights: | info:eu-repo/semantics/openAccess ; CC Attribution (CC BY) |
| Αριθμός Καταχώρησης: | edsbas.C5ECA672 |
| Βάση Δεδομένων: | BASE |
| DOI: | 10.1016/s2214-109x(22)00281-9 |
|---|